WO2008057966A3 - Panel de biomarqueurs de maladie d'artères périphériques - Google Patents
Panel de biomarqueurs de maladie d'artères périphériques Download PDFInfo
- Publication number
- WO2008057966A3 WO2008057966A3 PCT/US2007/083377 US2007083377W WO2008057966A3 WO 2008057966 A3 WO2008057966 A3 WO 2008057966A3 US 2007083377 W US2007083377 W US 2007083377W WO 2008057966 A3 WO2008057966 A3 WO 2008057966A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- biomarkers
- panel
- peripheral arterial
- arterial disease
- glucose
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/721—Haemoglobin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
- G01N33/721—Haemoglobin
- G01N33/723—Glycosylated haemoglobin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4737—C-reactive protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70539—MHC-molecules, e.g. HLA-molecules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
- G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- G01N2333/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
L'invention concerne des biomarqueurs comprenant de la ß-2-microglobuline, de la cystatine C, hsCRP et du glucose ainsi que les procédés d'utilisation de biomarqueurs pour le diagnostic et/ou l'évaluation du risque de maladie des artères périphériques chez un sujet. Dans certains modes de réalisation, le sujet testé peut souffrir de ou être prédisposé à d'autres maladies du système circulatoire, notamment de la maladie des artères coronaires. L'hémoglobine A1c ou d'autres mandataires pour la mesure des taux de glucose peuvent être substitués pour ou mesurés en plus du glucose dans le contexte de la présente invention.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86395106P | 2006-11-01 | 2006-11-01 | |
US60/863,951 | 2006-11-01 | ||
US92567807A | 2007-10-26 | 2007-10-26 | |
US11/925,678 | 2007-10-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008057966A2 WO2008057966A2 (fr) | 2008-05-15 |
WO2008057966A3 true WO2008057966A3 (fr) | 2008-07-03 |
Family
ID=39185656
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/083377 WO2008057966A2 (fr) | 2006-11-01 | 2007-11-01 | Panel de biomarqueurs de maladie d'artères périphériques |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008057966A2 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2469279A1 (fr) | 2006-03-11 | 2012-06-27 | The Board Of Trustees Of The Leland Stanford Junior University | Cystatin C, lysozyme et bêta-2 microglobuline en tant que biomarqueur d'une maladie des artères périphériques |
US8227201B2 (en) | 2007-06-27 | 2012-07-24 | Board Of Trustees Of The Leland Stanford Junior University | BETA2-microglobulin and C reactive protein (CRP) as biomarkers for peripheral artery disease |
WO2016197053A1 (fr) * | 2015-06-05 | 2016-12-08 | Beckman Coulter, Inc. | Panel de biomarqueurs de l'apnée obstructive du sommeil (aos) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1615036A1 (fr) * | 2004-07-07 | 2006-01-11 | F.Hoffmann-La Roche Ag | Combinaison de marqueurs pour le diabète de type 1 et 2 |
-
2007
- 2007-11-01 WO PCT/US2007/083377 patent/WO2008057966A2/fr active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1615036A1 (fr) * | 2004-07-07 | 2006-01-11 | F.Hoffmann-La Roche Ag | Combinaison de marqueurs pour le diabète de type 1 et 2 |
Non-Patent Citations (3)
Title |
---|
NEDELKOV DOBRIN ET AL: "Design and use of multi-affinity surfaces in biomolecular interaction analysis-mass spectrometry (BIA/MS): A step toward the design of SPR/MS arrays.", JOURNAL OF MOLECULAR RECOGNITION, vol. 16, no. 1, January 2003 (2003-01-01), pages 15 - 19, XP002475577, ISSN: 0952-3499 * |
SCHILLINGER MARTIN ET AL: "Joint effects of C-reactive protein and glycated hemoglobin in predicting future cardiovascular events of patients with advanced atherosclerosis.", CIRCULATION 11 NOV 2003, vol. 108, no. 19, 11 November 2003 (2003-11-11), pages 2323 - 2328, XP002475575, ISSN: 1524-4539 * |
STANDL E ET AL: "Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: The Munich General Practitioner Project", DIABETOLOGIA, vol. 39, no. 12, 1996, pages 1540 - 1545, XP009098445, ISSN: 0012-186X * |
Also Published As
Publication number | Publication date |
---|---|
WO2008057966A2 (fr) | 2008-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Eastwood et al. | Ethnic differences in associations between blood pressure and stroke in South Asian and European men | |
Ohya et al. | Increased pulse wave velocity is associated with low creatinine clearance and proteinuria in a screened cohort | |
Choi et al. | Relationship between brachial-ankle pulse wave velocity and cardiovascular risk factors of the metabolic syndrome | |
WO2006127861A3 (fr) | Diagnostic de maladies et d'etats pathologiques par l'analyse d'echantillons biologiques traites par voie histopathologique a l'aide de preparations tissulaires liquides | |
ATE545032T1 (de) | Diagnose von herz-kreislauf-erkrankung | |
WO2009090553A3 (fr) | Compositions et procédés de détection de peptides post-arrêts | |
WO2006014628A8 (fr) | Procédés d’évaluation des risques de développement de maladies cardio-vasculaires | |
Namasivayam et al. | Influence of aortic pressure wave components determined noninvasively on myocardial oxygen demand in men and women | |
WO2007147076A3 (fr) | Méthodes pour le diagnostic de caractères anormaux fœtaux | |
WO2008131361A3 (fr) | Biocapteurs pour mesurer des analytes dans le liquide interstitiel | |
Mulè et al. | Relationships between mild hyperuricaemia and aortic stiffness in untreated hypertensive patients | |
WO2010041046A3 (fr) | Protéines de granine en tant que marqueurs de maladie cardiaque | |
WO2006050479A3 (fr) | Compositions et methodes pour le diagnostic de troubles du colon | |
WO2006081521A3 (fr) | Methodes pour diagnostic et intervention de troubles hepatiques | |
EP2546649A3 (fr) | Biomarqueurs de la stéatose hépatique et procédés les utilisant | |
WO2007030928A3 (fr) | Methodes permettant de diagnostiquer les etats pathologiques dus au cancer colorectal et au cancer de l'ovaire | |
WO2005121362A3 (fr) | Methode de quantification selective d'isoformes de vegf dans un echantillon biologique et ses utilisations | |
WO2007032876A3 (fr) | Marqueurs biologiques associés à la dégénérescence maculaire liée à l'âge | |
CA2820841C (fr) | Biocapteur competitif a sensibilite accrue | |
WO2006116083A3 (fr) | Combinaison de dosage du 1,5-anhydroglucitol (1,5-ag) et de dosage du a1c/1,5-ag pour la mesure des variations de la glycemie dans le cas d'hyperglycemie generale et post-prandiale chez des patients diabetiques | |
CA2574417A1 (fr) | Timp-2 en tant que cible/marqueur de defaillance de cellules beta | |
WO2008057966A3 (fr) | Panel de biomarqueurs de maladie d'artères périphériques | |
WO2010138610A3 (fr) | Nouveaux sites de phosphorylation de la desmine utiles dans le diagnostic de maladies cardiaques et l'intervention dans le cadre de ces maladies | |
Bahrainwala et al. | Ambulatory Arterial Stiffness Index and circadian blood pressure variability | |
WO2008125681A8 (fr) | Moyens et procédés permettant d'évaluer le risque d'une intervention cardiaque chez des patients souffrant d'une maladie cardiaque coronarienne stable à partir de gdf-15 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07854559 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A OF 21-08-09) |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07854559 Country of ref document: EP Kind code of ref document: A2 |